Previous investigations have established Gal-LNP systems as effective carriers for hepatic-targeted delivery of both nucleic acids and small-molecule drugs in treating various liver disorders.45 The incorporation of galactose (Gal) modifications has substantially augmented the therapeutic value of LNPs in hepatology by enhancing cellular internalization efficiency and delivery precision, thereby optimizing treatment outcomes. This evidence concerns the gene GAL and liver disorder.